ATE445417T1 - Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung - Google Patents

Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Info

Publication number
ATE445417T1
ATE445417T1 AT01983146T AT01983146T ATE445417T1 AT E445417 T1 ATE445417 T1 AT E445417T1 AT 01983146 T AT01983146 T AT 01983146T AT 01983146 T AT01983146 T AT 01983146T AT E445417 T1 ATE445417 T1 AT E445417T1
Authority
AT
Austria
Prior art keywords
compositions
methods
nucleic acid
vivo methods
cells
Prior art date
Application number
AT01983146T
Other languages
English (en)
Inventor
Kevin J Donahue
Eduardo Marban
Koichi Nagata
John Lawrence
Original Assignee
Univ Johns Hopkins
Kevin J Donahue
Eduardo Marban
Koichi Nagata
Lawrence John H Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Kevin J Donahue, Eduardo Marban, Koichi Nagata, Lawrence John H Iii filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE445417T1 publication Critical patent/ATE445417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT01983146T 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung ATE445417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24023100P 2000-10-13 2000-10-13
PCT/US2001/032274 WO2002030470A1 (en) 2000-10-13 2001-10-15 Methods and compositions for nucleic acid delivery

Publications (1)

Publication Number Publication Date
ATE445417T1 true ATE445417T1 (de) 2009-10-15

Family

ID=22905689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01983146T ATE445417T1 (de) 2000-10-13 2001-10-15 Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung

Country Status (8)

Country Link
US (1) US6992070B2 (de)
EP (1) EP1331950B1 (de)
JP (1) JP2004534719A (de)
AT (1) ATE445417T1 (de)
AU (1) AU2002214596A1 (de)
CA (1) CA2425835A1 (de)
DE (1) DE60140200D1 (de)
WO (1) WO2002030470A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175790A1 (en) * 2000-09-06 2009-07-09 The Johns Hopkins University Cardiac arrhythmia treatment methods and biological pacemaker
JP5106738B2 (ja) * 2000-09-06 2012-12-26 ジョンズ・ホプキンス・ユニバーシティ 心不整脈治療法
AU2002214596A1 (en) 2000-10-13 2002-04-22 Kevin J. Donahue Methods and compositions for nucleic acid delivery
EP2314306A1 (de) * 2001-04-27 2011-04-27 Johns Hopkins University Biologisches Pacemaker
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
JP2006508073A (ja) * 2002-10-02 2006-03-09 ザ・ジョンズ・ホプキンス・ユニバーシティー 限局的カルシウムチャネル調節方法
MXPA05003771A (es) * 2002-10-09 2005-06-08 Pfizer Prod Inc Composiciones estabilizadas de adn desnudo.
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20060148742A1 (en) * 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US7722596B2 (en) * 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US20070203445A1 (en) * 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
US8759317B2 (en) * 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
WO2006074443A2 (en) 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
EP1850852A4 (de) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center Verwendung von sildenafil, vardenafil und anderen 5-phosphodiesterase-hemmern zur erhöhung der durchlässigkeit der abnormalen blut-hirn-schranke
JP2009511064A (ja) * 2005-10-14 2009-03-19 ザ ジョンズ ホプキンス ユニバーシティー 生物学的興奮性細胞
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US20090047703A1 (en) * 2007-08-17 2009-02-19 University Of Maryland, Baltimore ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
US20100041984A1 (en) * 2008-08-12 2010-02-18 James Edward Shapland Impedance sensing device and catheter system
US9050400B2 (en) * 2008-08-12 2015-06-09 Osprey Medical, Inc. Remote sensing catheter system and methods
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2013023126A2 (en) 2011-08-11 2013-02-14 Osprey Medical Inc. Systems and methods for limb treatment
CN103920161A (zh) * 2014-03-27 2014-07-16 浙江大学 一种在细胞膜微囊中高效装载药物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516651A (en) * 1991-11-15 1996-05-14 The General Hospital Corporation Nucleic acids encoding calcitonin receptor and uses thereof
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6237077B1 (en) 1997-10-13 2001-05-22 Idea Corporation Instruction template for efficient processing clustered branch instructions
WO1999031982A1 (en) 1997-12-19 1999-07-01 The Trustees Of The University Of Pennsylvania Transvascular delivery of a composition to an extravascular tissue of a mammal
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
AU2002214596A1 (en) 2000-10-13 2002-04-22 Kevin J. Donahue Methods and compositions for nucleic acid delivery

Also Published As

Publication number Publication date
WO2002030470A9 (en) 2003-02-06
EP1331950A1 (de) 2003-08-06
EP1331950B1 (de) 2009-10-14
JP2004534719A (ja) 2004-11-18
US6992070B2 (en) 2006-01-31
CA2425835A1 (en) 2002-04-18
AU2002214596A1 (en) 2002-04-22
DE60140200D1 (de) 2009-11-26
US20020094326A1 (en) 2002-07-18
WO2002030470A8 (en) 2004-04-08
WO2002030470A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
Keeney et al. The ability of a collagen/calcium phosphate scaffold to act as its own vector for gene delivery and to promote bone formation via transfection with VEGF165
Wu et al. DNA hydrogels and their derivatives in biomedical engineering applications
JP2019017390A (ja) 特定遺伝子の発現を抑制するための方法および薬剤
WO2020198509A3 (en) Modified oligonucleotides with increased stability
ATE340560T1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
KR102907044B1 (ko) 변형된 cpf1 가이드 rna
BRPI0410185A (pt) composição para manter a viabilidade de um orgão e célula
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
DE60144281D1 (de) Neues kationisches lipopolymer als biokompatible gentransfer-mittel
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
BR0014516A (pt) Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
WO2003068144A3 (en) Cytotoxic agents
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
Han et al. Harnessing nucleic acids nanotechnology for bone/cartilage regeneration
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
WO2008098569A3 (de) Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung
Hu et al. Mechanisms of hydrogel-based microRNA delivery systems and its application strategies in targeting inflammatory diseases
Li et al. Self‐Assembled DNA Composite‐Engineered Mesenchymal Stem Cells for Improved Skin‐Wound Repair
US10709759B1 (en) Self-replicating cell selective gene delivery compositions, methods, and uses thereof
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
ATE312173T1 (de) Methoden und zusammensetzungen zur aufklärung von proteinexpressionsprofilen in zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties